keyword
MENU ▼
Read by QxMD icon Read
search

metastatic prostate cancer

keyword
https://www.readbyqxmd.com/read/29916921/assessment-of-treatment-response-by-99mtc-mip-1404-spect-ct-a-pilot-study-in-patients-with-metastatic-prostate-cancer
#1
Christian Schmidkonz, Michael Cordes, Michael Beck, Theresa Ida Goetz, Daniela Schmidt, Olaf Prante, Tobias Bäuerle, Alexander Cavallaro, Michael Uder, Bernd Wullich, Peter Goebell, Torsten Kuwert, Philipp Ritt
BACKGROUND: We investigated the role of Tc-MIP-1404 (Progenics Pharmaceuticals, Inc, New York, NY) SPECT/CT of PSMA expression in the assessment of treatment response in patients with metastatic prostate cancer. METHODS: We retrospectively analyzed Tc-MIP-1404 SPECT/CT scans from 28 patients with metastatic prostate cancer examined before initiation and after completion of therapy. Eight of these patients had been treated with androgen deprivation therapy, 10 with docetaxel, and another 10 with external beam radiotherapy...
June 19, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29915723/bovine-milk-lactoferrin-selectively-kills-highly-metastatic-prostate-cancer-pc-3-and-osteosarcoma-mg-63-cells-in-vitro
#2
Joana P Guedes, Cátia S Pereira, Lígia R Rodrigues, Manuela Côrte-Real
Prostate cancer and osteosarcoma are the second most common type of cancer affecting men and the fifth most common malignancy among adolescents, respectively. The use of non-toxic natural or natural-derived products has been one of the current strategies for cancer therapy, owing to the reduced risks of induced-chemoresistance development and the absence of secondary effects. In this perspective, lactoferrin (Lf), a natural protein derived from milk, emerges as a promising anticancer agent due to its well-recognized cytotoxicity and anti-metastatic activity...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29915322/rare-germline-variants-in-dna-repair-genes-and-the-angiogenesis-pathway-predispose-prostate-cancer-patients-to-develop-metastatic-disease
#3
Martina Mijuskovic, Edward J Saunders, Daniel A Leongamornlert, Sarah Wakerell, Ian Whitmore, Tokhir Dadaev, Clara Cieza-Borrella, Koveela Govindasami, Mark N Brook, Christopher A Haiman, David V Conti, Rosalind A Eeles, Zsofia Kote-Jarai
BACKGROUND: Prostate cancer (PrCa) demonstrates a heterogeneous clinical presentation ranging from largely indolent to lethal. We sought to identify a signature of rare inherited variants that distinguishes between these two extreme phenotypes. METHODS: We sequenced germline whole exomes from 139 aggressive (metastatic, age of diagnosis < 60) and 141 non-aggressive (low clinical grade, age of diagnosis ≥60) PrCa cases. We conducted rare variant association analyses at gene and gene set levels using SKAT and Bayesian risk index techniques...
June 19, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29914515/clinical-trials-involving-positron-emission-tomography-and-prostate-cancer-an-analysis-of-the-clinicaltrials-gov-database
#4
Nikola Cihoric, Eugenia Vlaskou Badra, Alexandros Tsikkinis, Vikas Prasad, Stephanie Kroeze, Ivan Igrutinovic, Branislav Jeremic, Marcus Beck, Sebastian Zschaeck, Peter Wust, Pirus Ghadjar
BACKGROUND: The goal of this study is to evaluate the status and future perspectives of clinical trials on positron emission tomography in prostate cancer for diagnostic or therapeutic as well as for surveillance purposes. METHODS: The www.ClinicalTrials.gov database was searched on the 20th of January 2017 for all trials containing terms describing "prostate cancer" (prostate, prostatic, malignant, malignancy, cancer, tumor) and "positron emission tomography"...
June 18, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29914187/prostate-associated-gene-4-page4-leveraging-the-conformational-dynamics-of-a-dancing-protein-cloud-as-a-therapeutic-target
#5
REVIEW
Ravi Salgia, Mohit Kumar Jolly, Tanya Dorff, Clayton Lau, Keith Weninger, John Orban, Prakash Kulkarni
Prostate cancer (PCa) is a leading cause of mortality and morbidity globally. While genomic alterations have been identified in PCa, in contrast to some other cancers, use of such information to personalize treatment is still in its infancy. Here, we discuss how PAGE4, a protein which appears to act both as an oncogenic factor as well as a metastasis suppressor, is a novel therapeutic target for PCa. Inhibiting PAGE4 may be a viable strategy for low-risk PCa where it is highly upregulated. Conversely, PAGE4 expression is downregulated in metastatic PCa and, therefore, reinstituting its sustained expression may be a promising option to subvert or attenuate androgen-resistant PCa...
June 17, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29912284/epcr-an-r-package-for-survival-and-time-to-event-prediction-in-advanced-prostate-cancer-applied-to-real-world-patient-cohorts
#6
Teemu D Laajala, Mika Murtojärvi, Arho Virkki, Tero Aittokallio
Motivation: Prognostic models are widely used in clinical decision-making, such as risk stratification and tailoring treatment strategies, with the aim to improve patient outcomes while reducing overall healthcare costs. While prognostic models have been adopted into clinical use, benchmarking their performance has been difficult due to lack of open clinical datasets. The recent DREAM 9.5 Prostate Cancer Challenge carried out an extensive benchmarking of prognostic models for metastatic Castration-Resistant Prostate Cancer (mCRPC), based on multiple cohorts of open clinical trial data...
June 15, 2018: Bioinformatics
https://www.readbyqxmd.com/read/29911685/docetaxel-treatment-in-pten-and-erg-aberrant-metastatic-prostate-cancers
#7
Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, Susana Miranda, Diletta Bianchini, Zafeiris Zafeiriou, Spyridon Sideris, Ana Ferreira, Ines Figueiredo, Semini Sumanasuriya, Joaquin Mateo, Raquel Perez-Lopez, Adam Sharp, Nina Tunariu, Johann S de Bono
Background: Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) including abiraterone. The relationship between PTEN loss and docetaxel sensitivity remains uncertain. Objective: To study the antitumor activity of docetaxel in metastatic CRPC in relation to PTEN and ERG aberrations. Design setting and participants: Single-centre, retrospective analysis of PTEN loss and ERG expression using a previously described immunohistochemistry (IHC) binary classification system...
May 2018: European urology oncology
https://www.readbyqxmd.com/read/29909985/structural-alterations-driving-castration-resistant-prostate-cancer-revealed-by-linked-read-genome-sequencing
#8
Srinivas R Viswanathan, Gavin Ha, Andreas M Hoff, Jeremiah A Wala, Jian Carrot-Zhang, Christopher W Whelan, Nicholas J Haradhvala, Samuel S Freeman, Sarah C Reed, Justin Rhoades, Paz Polak, Michelle Cipicchio, Stephanie A Wankowicz, Alicia Wong, Tushar Kamath, Zhenwei Zhang, Gregory J Gydush, Denisse Rotem, J Christopher Love, Gad Getz, Stacey Gabriel, Cheng-Zhong Zhang, Scott M Dehm, Peter S Nelson, Eliezer M Van Allen, Atish D Choudhury, Viktor A Adalsteinsson, Rameen Beroukhim, Mary-Ellen Taplin, Matthew Meyerson
Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer (mCRPC), but there have been few whole-genome sequencing (WGS) studies of this disease state. We performed linked-read WGS on 23 mCRPC biopsy specimens and analyzed cell-free DNA sequencing data from 86 patients with mCRPC. In addition to frequent rearrangements affecting known prostate cancer genes, we observed complex rearrangements of the AR locus in most cases. Unexpectedly, these rearrangements include highly recurrent tandem duplications involving an upstream enhancer of AR in 70%-87% of cases compared with <2% of primary prostate cancers...
June 11, 2018: Cell
https://www.readbyqxmd.com/read/29907594/repositioning-dopamine-d2-receptor-agonist-bromocriptine-to-enhance-docetaxel-chemotherapy-and-treat-bone-metastatic-prostate-cancer
#9
Yang Yang, Kenza Mamouni, Xin Li, Yanhua Chen, Sravan Kavuri, Yuhong Du, Haian Fu, Omer Kucuk, Daqing Wu
Docetaxel resistance remains a major obstacle in the treatment of prostate cancer (PCa) bone metastasis. In this study, we demonstrate that the dopamine D2 receptor (DRD2) agonist bromocriptine effectively enhances docetaxel efficacy and suppresses skeletal growth of PCa in preclinical models. DRD2 is ubiquitously expressed in PCa cell lines, and DRD2 is significantly reduced in PCa tissues with high Gleason score. Bromocriptine has weak to moderate cytotoxicity in PCa cells, but effectively induces cell cycle arrest...
June 15, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29906450/inactivation-of-cdk12-delineates-a-distinct-immunogenic-class-of-advanced-prostate-cancer
#10
Yi-Mi Wu, Marcin Cieślik, Robert J Lonigro, Pankaj Vats, Melissa A Reimers, Xuhong Cao, Yu Ning, Lisha Wang, Lakshmi P Kunju, Navonil de Sarkar, Elisabeth I Heath, Jonathan Chou, Felix Y Feng, Peter S Nelson, Johann S de Bono, Weiping Zou, Bruce Montgomery, Ajjai Alva, Dan R Robinson, Arul M Chinnaiyan
Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer (mCRPC) samples, we identified a novel subtype of prostate cancer typified by biallelic loss of CDK12 that is mutually exclusive with tumors driven by DNA repair deficiency, ETS fusions, and SPOP mutations. CDK12 loss is enriched in mCRPC relative to clinically localized disease and characterized by focal tandem duplications (FTDs) that lead to increased gene fusions and marked differential gene expression. FTDs associated with CDK12 loss result in highly recurrent gains at loci of genes involved in the cell cycle and DNA replication...
June 14, 2018: Cell
https://www.readbyqxmd.com/read/29906246/o-glycosylation-mediated-signaling-circuit-drives-metastatic-castration-resistant-prostate-cancer
#11
Sheue-Fen Tzeng, Chin-Hsien Tsai, Tai-Kuang Chao, Yu-Ching Chou, Yu-Chih Yang, Mong-Hsun Tsai, Tai-Lung Cha, Pei-Wen Hsiao
Disseminated castration-resistant prostate cancer (CRPC) is a common disease in men that is characterized by limited survival and resistance to androgen-deprivation therapy. The increase in human epidermal growth factor receptor 2 (HER2) signaling contributes to androgen receptor activity in a subset of patients with CRPC; however, enigmatically, HER2-targeted therapies have demonstrated a lack of efficacy in patients with CRPC. Aberrant glycosylation is a hallmark of cancer and involves key processes that support cancer progression...
June 15, 2018: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/29905090/narrative-medicine-in-metastatic-prostate-cancer-reveals-ways-to-improve-patient-awareness-quality-of-care
#12
Giuseppe De Vincentis, Fabio Monari, Sergio Baldari, Matteo Salgarello, Viviana Frantellizzi, Elisabetta Salvi, Luigi Reale, Silvia Napolitano, Giario Conti, Enrico Cortesi
AIM: To describe the journey of patients with metastatic castration-resistant prostate cancer (mCRPC) in treatment with radium-223. METHODS: A multiperspective analysis was performed using narrative medicine in four Italian centers. RESULTS: The substantial impact of mCRPC on quality of life through all phases of the disease was described. After an initial lack of awareness of the disease or denial of its effects, symptoms of pain, fatigue and side effects often led to sadness, fear and loneliness...
June 15, 2018: Future Oncology
https://www.readbyqxmd.com/read/29904742/factors-influencing-prostate-cancer-patterns-of-care-an-analysis-of-treatment-variation-using-the-seer-database
#13
Lindsay M Burt, Dennis C Shrieve, Jonathan D Tward
Purpose: The aim of this study is to describe the trends and factors that influence the initial treatment of men with localized prostate cancer (PC) in the United States between 2004 and 2014. Methods and materials: The National Cancer Institute's Surveillance, Epidemiology and End Results database was used to identify patients with primary prostate adenocarcinoma between 2004 and 2014. Patients were staged in accordance with the American Joint Committee on Cancer 7th edition criteria and stratified according to the National Comprehensive Cancer Network guidelines risk group classification...
April 2018: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/29904592/prostate-specific-antigen-psa-kinetic-as-a-prognostic-factor-in-metastatic-prostate-cancer-receiving-androgen-deprivation-therapy-systematic-review-and-meta-analysis
#14
Andika Afriansyah, Agus Rizal Ardy Hariandy Hamid, Chaidir Arif Mochtar, Rainy Umbas
Aim: Metastatic prostate cancer (mPCa) has a poor outcome with median survival of two to five years. The use of androgen deprivation therapy (ADT) is a gold standard in management of this stage.  Aim of this study is to analyze the prognostic value of PSA kinetics of patient treated with hormonal therapy related to survival from several published studies Method: Systematic review and meta-analysis was performed using literature searching in the electronic databases of MEDLINE, Science Direct, and Cochrane Library...
2018: F1000Research
https://www.readbyqxmd.com/read/29901632/alloreactive-cytotoxic-t-lymphocyte-immunotherapy-treatment-of-a-patient-with-metastatic-prostate-cancer-a-case-report
#15
Junfeng Shi, Yi Chen, Yuetong Chen, Yunzhu Shen, Huanyu Zhao, Hui Sun, Jinfei Chen
RATIONALE: Cytotoxic T lymphocyte (CTL) immunotherapy is an autologous cellular immune therapy that has been approved for treating patients with malignant tumors. However, there is still limited information regarding the impact of CTL on metastatic prostate cancer (PC) patients with bone metastatic lesions. PATIENT CONCERNS: An 82-year-old male patient complained of interrupted urination, urination pain, and significant dysuria on November 24, 2014. Transurethral resection of the prostate (TURP) and postoperative pathological examination showed prostatic adenocarcinoma, and a SPECT/CT scan demonstrated multiple bone metastases...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29900882/impact-of-taxanes-on-androgen-receptor-signaling
#16
REVIEW
Shanshan Bai, Bryan Y Zhang, Yan Dong
The development and progression of metastatic castration-resistant prostate cancer is the major challenge in the treatment of advanced prostate cancer. The androgen receptor signaling pathway remains active in metastatic castration-resistant prostate cancer. Docetaxel and cabazitaxel are the first- and second-line chemotherapy, respectively, for patients with metastatic castration-resistant prostate cancer. These two taxanes, in general, function by (i) inhibiting mitosis and inducing apoptosis and (ii) preventing microtubule-dependent cargo trafficking...
June 12, 2018: Asian Journal of Andrology
https://www.readbyqxmd.com/read/29899810/gene-therapy-with-rala-inos-composite-nanoparticles-significantly-enhances-survival-in-a-model-of-metastatic-prostate-cancer
#17
Cian M McCrudden, John W McBride, Joanne McCaffrey, Emma M McErlean, Nicholas J Dunne, Vicky L Kett, Jonathan A Coulter, Tracy Robson, Helen O McCarthy
Background: Recent approvals of gene therapies by the FDA and the EMA for treatment of inherited disorders have further opened the door for assessment of nucleic acid pharmaceuticals for clinical usage. Arising from the presence of damaged or inappropriate DNA, cancer is a condition particularly suitable for genetic intervention. The RALA peptide has been shown to be a potent non-viral delivery platform for nucleic acids. This study examines the use of RALA to deliver a plasmid encoding inducible nitric oxide synthase (iNOS) as an anti-cancer treatment...
2018: Cancer Nanotechnology
https://www.readbyqxmd.com/read/29896282/aerosol-immunotherapy-with-or-without-cisplatin-for-metastatic-lung-cancer-non-small-cell-lung-cancer-disease-in-vivo-study-a-more-efficient-combination
#18
Konstantinos Sapalidis, Paul Zarogoulidis, Efstathios Pavlidis, Stella Laskou, Athanasios Katsaounis, Charilaos Koulouris, Dimitrios Giannakidis, Stylianos Mantalovas, Haidong Huang, Chong Bai, Yuting Wen, Li Wang, Chrysanthi Sardeli, Aikaterini Amaniti, Ilias Karapantzos, Chrysanthi Karapantzou, Wolfgang Hohenforst-Schmidt, Fotis Konstantinou, Isaak Kesisoglou, Naim Benhanseen
Lung cancer is the leading cause of cancer death after prostate cancer for males and breast cancer for females. There are novel therapies in the past five years such as; tyrosine kinase inhibitors and most recently in the last two years immunotherapy. Immunotherapy is currently being investigated if it can be administered alone or in combination. Previously we have investigated whether immunotherapy compounds can be produced as aerosols, and in the current study we investigated the safety and efficiency independently of the programmed death-ligand 1...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29894335/evidence-of-prostate-specific-membrane-antigen-expression-in-metastatic-differentiated-thyroid-cancer-using-68ga-psma-hbed-cc-pet-ct
#19
Priyanka Verma, Gaurav Malhotra, Ritesh Agrawal, Sunita Sonavane, Vilas Meshram, Ramesh V Asopa
PURPOSE OF THE REPORT: Prostate-specific membrane antigen (PSMA) overexpression is not restricted to prostate cancer, but it has also been demonstrated in gliomas, lung cancer, and in tumor neovasculature. Systematic studies exploring PSMA uptake in thyroid tumors are lacking. The aim of this pilot study was to assess PSMA expression in patients with metastatic differentiated thyroid cancer (mDTC). MATERIALS AND METHODS: Ten patients of mDTC harboring 32 lesions (5 men; age range, 38-65 years; mean age, 50 years) underwent prospective evaluation with radioiodine (I), F-FDG PET, and Ga-PSMA-HBED-CC PET scans as per the institution protocol...
June 12, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29894275/circulating-tumor-cell-number-as-a-response-measure-of-prolonged-survival-for-metastatic-castration-resistant-prostate-cancer-is-real-circulating-tumor-cell-number-superior-to-prostate-specific-antigen
#20
Chuanli Ren, Chongxu Han, Daxin Wang, Hui Chen
No abstract text is available yet for this article.
June 12, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
30125
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"